SCHEMBL24717962

SCHEMBL24717962

C1CC(CN2CC3(CCNC3)C2)CCN1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.45
GBA1 P04062 2/20 0.38
CYP2D6 P10635 6/20 0.35
ARG1 P05089 1/20 0.33
ARG2 P78540 1/20 0.33
L3MBTL3 Q96JM7 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CYP3A4 P08684 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP2C19 P33261 1/20 0.31
SIGMAR1 Q99720 2/20 0.31
CACNA2D1 P54289 1/20 0.31
CACNA1B Q00975 1/20 0.31
CACNB1 Q02641 1/20 0.31
SCN1A P35498 1/20 0.31
SCN4A P35499 1/20 0.31
SCN7A Q01118 1/20 0.31
KCNH2 Q12809 1/20 0.31
SCN5A Q14524 1/20 0.31
SCN9A Q15858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25924736 0.88 TSHR (0.57) TSHRGBA1CYP2D6L3MBTL3L3MBTL1
SCHEMBL24717722 0.83 TSHR (0.47) TSHRCYP2D6L3MBTL3L3MBTL1CYP3A4
SCHEMBL29317112 0.79 CYP2D6 (0.50) TSHRGBA1CYP2D6CYP3A4ALDH1A1
SCHEMBL23588942 0.77 SCN1A (0.36) TSHRGBA1SIGMAR1SCN1ASCN4A
SCHEMBL30121551 0.76 GBA1 (0.39) TSHRGBA1CYP2D6ARG1ARG2
SCHEMBL24267132 0.76 GBA1 (0.36) TSHRGBA1CYP2D6ARG1ARG2
SCHEMBL27268150 0.76 TSHR (0.39) TSHRGBA1CYP2D6CYP3A4ALDH1A1
SCHEMBL24717358 0.76 CYP2D6 (0.36) TSHRGBA1CYP2D6CYP3A4ALDH1A1
SCHEMBL25856124 0.76 CYP2D6 (0.41) TSHRCYP2D6CYP3A4ALDH1A1CYP2C19
SCHEMBL24267397 0.75 GBA1 (0.36) TSHRGBA1ARG1ARG2CACNA2D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 TSHR 3100/4885GBA1 2636/4885CYP2D6 4179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.